Compare NAKA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAKA | HUMA |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 165.7M |
| IPO Year | 2023 | 2020 |
| Metric | NAKA | HUMA |
|---|---|---|
| Price | $5.65 | $0.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.33 | $1.63 |
| AVG Volume (30 Days) | 167.1K | ★ 5.9M |
| Earning Date | 11-18-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.19 | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | $3,833.87 | $72.32 |
| Revenue Next Year | N/A | $518.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.33 | $0.34 |
| 52 Week High | $640.80 | $1.53 |
| Indicator | NAKA | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 48.49 |
| Support Level | $4.38 | $0.34 |
| Resistance Level | $7.59 | $0.46 |
| Average True Range (ATR) | 0.62 | 0.05 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 11.82 | 43.92 |
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.